UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________ FORM 10-K _________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-5353 ____________________________ ...

Key Takeaways TFX Q4 adjusted EPS rose 1% to $1.93 but missed estimates by 48.3%, with revenues below consensus. Teleflex's gross margin fell 678 bps to 54% as costs jumped 51%, pressuring operating profit. TFX expects 2026 GAAP revenue growth of 14.4-15.4% and adjusted EPS of $6.25-$6.55. Teleflex Incorporated (TFX) posted fourth-quarter 2025 adjusted earnings per share (EPS) from continuing operations of $1.93, up 1% from the year-ago quarter’s figure. The metric missed the Zacks Consensus Estimate by 48. ...

Teleflex (NYSE:TFX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBradley Bowers - VP of Equity ResearchJayson Bedford - Managing Director of Equity ResearchJohn Deren - EVP and CFOLawrence Keusch - Vice President of Investor Relations and Strategy DevelopmentStuart Randle - Interim President and CEOTravis Steed - Managing Director of Medical Technology Equity ResearchConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMatthew O'Brien - Managi ...

Teleflex (NYSE:TFX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBradley Bowers - VP of Equity ResearchJayson Bedford - Managing Director of Equity ResearchJohn Deren - EVP and CFOLawrence Keusch - Vice President of Investor Relations and Strategy DevelopmentStuart Randle - Interim President and CEOTravis Steed - Managing Director of Medical Technology Equity ResearchConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMatthew O'Brien - Managi ...

An audio replay of the call will be available beginning either on the Teleflex website or by telephone. Teleflex Incorporated Year-End 2025 Earnings Conference Call 2/26/2026 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. at 11:00 am Eastern Time on February 26, 2026 Today's Speakers St ...

Wall Street analysts forecast that Teleflex (TFX) will report quarterly earnings of $3.73 per share in its upcoming release, pointing to a year-over-year decline of 4.1%. It is anticipated that revenues will amount to $925.96 million, exhibiting an increase of 16.4% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed t ...

Core Viewpoint - Teleflex Incorporated will host a conference call on February 26, 2026, to discuss its fourth quarter 2025 financial results and provide an operational update [1] Company Information - Teleflex is a global provider of medical technologies focused on improving health and quality of life [1] - The company aims to become the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [1] - Teleflex's product brands include Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [1] Conference Call Details - The conference call is scheduled for 8:00 a.m. Eastern Time on February 26, 2026 [1] - Participants can pre-register for the call through a provided link and access it via a live audio webcast on the company's website [1] - An audio replay will be available starting at 11:00 a.m. Eastern Time on the same day, accessible through the Teleflex website or by telephone [1]

Investment Rating - The report suggests a focus on Haisheng Medical as a leading player in the anesthesia and monitoring medical device sector, recommending attention to the company [4][5]. Core Insights - Haisheng Medical is set to issue shares at a price of 12.64 CNY per share with an initial issuance of 11.29 million shares, representing 15% of the total post-issue share capital [4][7]. - The company has a projected total investment of 482.7 million CNY for its fundraising projects, primarily aimed at upgrading and automating its anesthesia monitoring emergency medical devices [4][10]. - The company reported a net profit of 58.78 million CNY for Q1-Q3 2025, reflecting a year-on-year increase of 26.70% [4][12]. - The global low-value consumables market is expected to grow steadily, potentially reaching 129.82 billion USD by 2030, with the Chinese market for low-value medical consumables projected to reach 221.3 billion CNY by 2025 [4][14][18]. Company Overview - Haisheng Medical, established in 2000, specializes in anesthesia and monitoring medical devices, achieving a net profit of 78.04 million CNY in 2023, a year-on-year increase of 11% [4][12]. - The company has developed a comprehensive product matrix covering eight major series, including airway and respiratory management, life information monitoring, and nerve block products [4][14]. - As of November 13, 2025, the company holds 63 national authorized patents, including 13 invention patents, and has 53 medical device registrations [4][14]. Market Potential - The global medical device market is projected to grow from 479.36 billion USD in 2023 to 637.96 billion USD by 2028, with China's medical device market expected to reach 1.66 trillion CNY by 2030 [4][14]. - The demand for low-value medical consumables in China is anticipated to grow rapidly, with the market size expected to reach 221.3 billion CNY in 2025 [4][18]. Subscription Recommendation - Haisheng Medical is positioned as a leading supplier in the anesthesia and monitoring medical device sector, with a strong focus on product quality and continuous technological innovation [4][12].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Teleflex Incorporated and its executives following the abrupt departure of CEO Liam Kelly, which led to a significant drop in the company's stock price [1][3]. Group 1: Company Developments - On January 8, 2026, Teleflex announced the immediate departure of Liam Kelly as Chairman, President, and CEO [3]. - Following this announcement, Teleflex's stock price decreased by $16.52 per share, representing a 13.06% decline, closing at $110.01 per share [3]. Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Teleflex regarding possible securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].

Core Viewpoint - Teleflex Incorporated (TFX) experienced a significant decline in share price following leadership changes and a lowered revenue outlook for the year [1]. Group 1: Leadership Changes - Stuart Randle has been appointed as Interim President and Chief Executive Officer, effective immediately, succeeding Liam Kelly, who has stepped down from his roles as Chairman, President, and CEO [1]. Group 2: Stock Performance - Shares of Teleflex fell by 11.32 percent, dropping $14.32 to $112.21 from a previous close of $126.53 [1][2]. - The stock opened at $112.50 and traded within a range of $108.39 to $115.00 during the session on the New York Stock Exchange [2]. - Trading volume reached approximately 1.38 million shares, significantly higher than the average volume of about 0.64 million shares [3]. Group 3: Historical Context - Teleflex's shares have fluctuated within a 52-week range of $102.58 to $185.94 [3].